Profile data is unavailable for this security.
About the company
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
- Revenue in DKK (TTM)176.95bn
- Net income in DKK55.53bn
- LocationNovo Nordisk A/SNovo Alle 1BAGSVAERD 2880DenmarkDNK
- Phone+45 44448888
- Fax+45 44436633
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|NOVO B:CPH since |
|Forma Therapeutics Holdings Inc||Deal completed||01 Sep 2022||01 Sep 2022Deal completed||37.01%||1.11bn|
|Marinus Pharmaceuticals Inc-Priority Review Voucher||Announced||14 Jul 2022||14 Jul 2022Announced||34.02%||110.00m|